Last week’s negative FDA advisory committee vote may be the final nail in the coffin in the up-and-down registration path of Biogen...
AVXL stock was a big winner for us here at Insider Financial back in 2015 when we caught the run from $1 to...
In true fashion and as predicted, 2019 is turning out to be a big year for Anavex Life Sciences Corp (NASDAQ: AVXL)....
After the news broke that Biogen Inc (NASDAQ: BIIB) and development partner Eisai (OTCMKTS: ESALY) decided to terminate two late-stage studies, ENG...
So far, 2019 is looking promising for Anavex Life Sciences Corp (NASDAQ:AVXL). AVXL is a stock that we have covered quite extensively here...
Anavex Life Sciences Corp (NASDAQ:AVXL) was one of Insider Financial’s top runners a few years back. We covered the stock extensively and...
A disappointing earnings report is the last thing that Anavex Life Sciences Corp. (NASDAQ:AVXL) needed, after plummeting to all-time lows. Investors’ confidence...
Anavex Life Sciences Corp (NASDAQ:AVXL), the clinical stage biopharmaceutical developing treatments for neurodegenerative and neurodevelopmental diseases, has been recently under the radar...